BALTIMORE ( Stockpickr) -- Capitol Hill looks to lead off the market for a second consecutive week, now that the health care reform bill has passed the House. While some risk has already been priced into health stocks, now that a reform bill has been passed, expect to see stocks show a mild response. Expect the biggest weight on Wall Street on Monday to be how it's being paid for: with an increase in taxes on investment income.

In its current incarnation, health insurers should bare the brunt of the legal changes, but don't be surprised to see more than a few health care stocks rally on health reform news. Increased government spending will essentially turn into a long-term stimulus package for companies that provide things such as medical products and services to patients.

One of this week's Rocket Stock plays could capitalize on that.

Rocket Stocks, our weekly list of beaten-down stocks with near-term growth catalysts and long-term growth potential, seek to separate the cream from the investing crop. In the last five trading days, our five Rocket Stock picks have delivered 0.52% gains, slipping our performance over the S&P in the trailing 35 weeks to 44.7%.

That means that since last July, investing in our weekly list at each Monday's open and selling at the following Friday's close would have yielded 68.05% gains to date.

Here's a look at this week's five Rocket Stocks plays.

Despite single-digit gains in oil prices this year, shares of PetroChina ( PTR) have been off to a slow start. But the Chinese oil and gas supermajor should be catching additional investor attention as it expands its limited reserve capacities and becoming a more relevant global player in the industry. An earnings release today stands to sway additional investors this week.

PetroChina is an interesting beast. The company is China's lone supermajor, a distinction that was initially met with exuberance as investors tried to snap up shares of this Far East power play. But cooler heads have put a stop to the bull run thanks to a global recession and clearly limited resource supplies in mainland China.

That could be changing, however. As China continues to grow -- the country's oil consumption is expected to grow at 7.5% annually -- demand for oil will continue to be a driving force for PetroChina's share price. And PTR's supply should be less of a constraint; the company has worked hard to expand its interests abroad, purchasing stakes in 12 additional countries in the last few years. And unlike its Western competitors, the involvement of the Chinese government in PTR's operations (the People's Republic owns 86% of the company) means that the company has added political clout in its negotiations.

Wall Street is decidedly bearish on PetroChina's annual earnings release today. But that could present us with a strong contrarian play to start the week. We're going long at Monday's open, while investors stay transfixed on the company's pending joint acquisition of Australian gas producer Arrow Energy -- and the rest wait on earnings before making their moves.

Regardless of which side of the health care reform aisle you sit on, it's clear that some health stocks are going to benefit in a big way from additional dollars now that the current bill has become the law of the land. Among them are pharmacy stocks.

With the potential for new taxpayer dollars to be spent on pharmaceuticals, big pharma, generic drug makers, and the pharmacies have been rallying around the idea of reform -- and putting up serious cash to help grease the wheels. But retail pharmacy chain Walgreen ( WAG) looks like one of the most compelling plays right now. Last month, the company, which operates nearly 7,500 brick-and-mortar locations in 50 states, announced plans to acquire New York City drugstore chain Duane Reed in a billion-dollar deal that would make Walgreen the leading drugstore chain in the biggest pharmacy market in the nation.

Taking advantage of bargain M&A prices is a smart move for Walgreen, which is already benefitting from increased consumer discretionary spending at its retail locations, and increased spending through its mail-order drug business. As one of the leading players in a fairly recession resistant niche, the company should continue to thrive in 2010. Earnings this week could be the catalyst for significantly higher share prices in March.

Apparel retailer Phillips-Van Heusen ( PVH) is already having a breakout month, with shares up more than 26% following the company's announcement that it would add Tommy Hilfiger to its portfolio of brands. The move was a coup for the apparel industry, which has been lodged in a fierce fight for fewer consumer dollars in the last couple of years.

But it should prove to be a strategically significant buy for the dress shirt giant. The company's previous forays into bigger brand names have already carved out bigger margins and increased sales numbers, and with a bargain price tag on the Tommy acquisition, PVH should be able to integrate the iconic label into its portfolio without too much rigmarole.

Watch for shares to bump following this week's earnings call, which should provide increased insights into the purchase.

For more stocks that made this week's cut, including Coca-Cola ( KO) and Lloyds Banking Group ( LYG), check out the Rocket Stocks portfolio at Stockpickr.

-- Written by Jonas Elmerraji in Baltimore.
Jonas Elmerraji is the editor and portfolio manager of the Rhino Stock Report, a free investment advisory that returned 15% in 2008. He is a contributor to numerous financial outlets, including Forbes and Investopedia, and has been featured in Investor's Business Daily, in Consumer's Digest and on